three weeks of a menstrual cycle. No medication is given in the fourth week.
Age 40-49 (theperimenopausal era): Menstruation is usually irregular and scanty. Typical symptoms and physical signs of cestrogen deficiency are often present. Premarin 1.25 mg daily is given for 20 days from Day 5 to Day 24. In addition, Provera is given for the last 10 days. Norethisterone (Norlutin) is used instead of Provera in patients with fibrocystic disease of the breast.
Age 50-69 (the postmenopausal era): The vaginal smear reads 10-80-0. Symptoms are usually present. Premarin 1.25 mg or 2.5 mg is given daily for 40, 50 or 60 days, supplemented by Provera 10 mg for the last 10 days. If withdrawal bleeding is not desired, methyltestosterone 10 mg daily is given instead of Provera. At the beginning of therapy it is sometimes helpful to administer cestradiol benzoate (Progynon) 1.5 mg i.m. once or twice instead of the oral aestrogen.
Age 70-85 (the geriatric era or the adrenopause):
The vaginal smear reads 0-30-70. Premarin 2.5 mg daily is given for 40, 50 or 60 days, supplemented with methyl testosterone 10 mg during the last 10 days. The course is repeated after a rest of 7 days.
Conclusion
The modern physician, especially the gynecologist, has many therapeutic measures and techniques available for helping the menopausal woman, and in fact can help the menopausal couple to attain a high measure of physical, mental and sexual comfort and fulfilment during the many years that lie ahead.
Professor Sir John Stallworthy (Nuffield Department of Obstetrics and Gynecology, Oxford) commented on the fact that there were said to be 14 million women in the United States suffering from osteoporosis.
The thought of this vast group getting shorter in stature, bowed in back, and suffering constant pain from skeletal rarefaction was terrifying. Conversely, the prospect of preventing this suffering by the administration of Premarin, as implied if not actually stated by Dr Zussman, would have a tremendous appeal if there were scientific evidence to confirm its efficacy. He wondered whether osteoporosis was diagnosed clinically, radiologically, or biochemically? What evidence suggested that the changes, however they were diagnosed, could be prevented or cured by administering conjugated cestrogens? British experts had not apparently heard of any such evidence. Enquiry at the bone metabolism unit of the Nuffield Orthopedic Centre resulted in the often repeated statement that the whole question of the etiology, pathology and therapy of osteoporosis was difficult and as yet unsolved. Evidence to prove that this was an unjustifiable attitude would be welcomed.
Sir John thought that few, if any, would disagree with Dr Zussman that the administration of aestrogen could be of great value to women troubled by the menopausal syndrome. Many used this treatment extensively. For example, at Oxford whenever hysterectomy was performed in the reproductive age and it was found necessary to remove ovaries, an implant of cestradiol 100 mg was inserted in the abdominal wall as the incision was closed. Extensive experience confirmed that patients could be assured before operation that they would have no postoperative menopausal side-effects. Hormonal assays had confirmed that the blood oestrogen levels remained raised and the gonadotrophin levels depressed for over a year following this single implant. But this was a selected group; obviously one would not use such an implant in a woman who still had her uterus. He thought that the point at issue was that there was a difference between treating patients with hormones when they needed it as opposed to routine treatment of all members of the population whether they had symptoms or not. The creative power of the Almighty in designing the human body should not be underestimated. Countless numbers of elegant, happy, healthy postmenopausal women enjoyed life with no apparent need for hormone therapy.
Finally, he made reference to what Dr Zussman described as the premature menopause in the age group 14 to 29. This diagnosis, which could certainly cause considerable distress to many young healthy women, appeared to be made from vaginal cytology without reference to general health and development. If this was so, a logical question to be answered was why not include in the 'premature menopause group' every female infant whose vagina ceased to be influenced by the maternal aestrogen which nourished it in utero ?
Conflicting evidence had been presented concerning the incidence of hypertension associated with the administration of oral contraceptives and nothing had been said about changes in the clotting factors during cestrogen therapy. He hoped that Dr Zussman and his team proposed to investigate these important issues in the prospective scientific study which they planned. If they confirmed the work of others indicating that changes might occur which could be serious this would provide arguments against routine postmenopausal cestrogen therapy. Dr Zussman had correctly said that there were many therapeutic measures now available for helping menopausal and postmenopausal women. However, Sir John concluded that there was, in his opinion, no scientific evidence to support the universal administration of hormones.
Professor Peter Curzen (Westminster Medical School, London SWI) said that Dr Zussman's paper had been both stimulating and provocative. There was general acceptance of the view that women with menopausal symptoms should be treated. Furthermore, the short-term systemic administration of aestrogens constituted an important facet of such treatment. However, Dr Zussman seemed to advocate long-term prophylactic administration of cestrogens for the remainder of the postmenopausal woman's life. His principal argument in support of this view was that prophylactic cestrogens should reduce the incidence and severity of those degenerative processes which often become accelerated after the menopause, and which interfere with the psychological, somatic and sexual wellbeing of the postmenopausal patient.
There was certainly considerable biochemical, radiological and epidemiological evidence to show that the incidence of osteoporosis increases after the menopause. There was also some evi-dence that the biochemical disturbances characteristic of osteoporosis could be prevented, but not reversed, by oestrogen therapy. However, the incidence of symptomatic as distinct from asymptomatic osteoporosis had not been clearly established, and it was difficult to assess how much of a clinical problem this constituted.
There was also considerable evidence to support the view that the much lower incidence of major cardiovascular disease in premenstrual women as compared with men might be due to aestrogens. After the menopause this difference in incidence greatly lessened, until the eighth decade of life, when the incidence was approximately the same in both sexes. Plasma levels of cholesterol, phospholipids and triglycerides tended to rise after the menopause. High levels of these substances were often associated with major cardiovascular disease and had been incriminated as a causative factor in such diseases by some workers. The administration of systemic estrogens tended to reduce plasma levels of these substances in postmenopausal women. However, there was no evidence to show that systemic cestrogens reduced the incidence of major cardiovascular disease after the menopause. Even if they did, the possible domestic and social consequences of artificially maintaining the sex differential for major cardiovascular disease in the later decades of life would require careful consideration.
Dr Zussman considered that the postmenopausal administration of cestrogens was important to maintain the libido as well as the frequency and quality ofcoitus. However, it had been shown that in many postmenopausal women not receiving cestrogens, sexual function improved spontaneously as a result of freedom from the fear of a possible pregnancy. Furthermore, sexual function after the menopause appeared to be closely related to its function before.
Dr Zussman's enthusiasm for the long-term prophylactic use ofcestrogens after the menopause was obviously based on a very strong sense of personal conviction which was shared by his co-workers. However, in Professor Curzen's opinion, statistical proof was lacking and could only be provided by a properly controlled trial. Even if such a trial substantiated the usefulness of this form of treatment, its possible widespread implementation within our National Health Service would have to be considered carefully in relation to other priorities.
